Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
This study is completed. It focuses on ADHD and currently lists study information in the United States.
ADHDDrugFrom 6 Years to 12 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether amphetamine extended-release oral suspension, 2.5 mg/mL may be useful for children experiencing ADHD.
What would participation involve?
Participants may receive amphetamine extended-release oral suspension, 2.5 mg/mL, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
